title: HIV-1 DNA and RNA kinetics in primary HIV infection.
abstract: BACKGROUND
  HIV-1 reservoir is early established during PHI. It is reduced, but not extinguished by early therapy: DNA containing cells are still detectable after months of successful viremia suppression. To define the best method to measure low level viral replication, we determined the extent of HIV reservoir in 11 acutely infected patients and evaluated how it is renewed even during successful treatment.
  
  
  METHODS
  Eleven acutely infected HIV patients were included in the study. Three where not treated with antiretroviral drugs while 8 underwent early aggressive antiretroviral treatment (HAART) which, in 3 cases, was associated to cyclosporin A (CsA) administration. HIV viremia was monitored by commercially available methods while HIV-DNA and cellular RNA quantitation were obtained by in house PCR and RT-PCR respectively, in the gag region.
  
  
  RESULTS
  Significant CD4 recover and HIV viremia suppression were reached in a mean period of three to six months in all treated patients. The course of the HIV-DNA and of cellular HIV RNA reduction showed a similar trend. This variation was slower, if compared to plasma viremia and never reached undetectable levels, justifying the rebound of viremia observed at therapy interruption.
  
  
  CONCLUSIONS
  These data suggest and confirm that complete abolition of viral replication is not achieved and viral reservoir may be re-expanded even after short term rebound of viremia. Scheduling of possible structured therapy interruption should be designed based on multiple virological parameters and on the individual characteristics of the patients.
authors: Laboratory of Virology, Scientific Institute San Raffaele, Milan, Italy. lillo.flavia@hsr.it
authors: F
authors: F
authors: Lillo
authors: M
authors: M
authors: Grasso
authors: S
authors: S
authors: Lodini
authors: B
authors: B
authors: Capiluppi
authors: A
authors: A
authors: Lazzarin
authors: G
authors: G
authors: Tambussi
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D016572:Cyclosporine / Q000494:pharmacology / Q000627:therapeutic use; D004279:DNA, Viral / Q000097:blood*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D007700:Kinetics; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D011533:Proviruses / Q000302:isolation & purification; D012367:RNA, Viral / Q000097:blood*; D019562:Viral Load; D014766:Viremia / Q000188:drug therapy / Q000821:virology*; D014779:Virus Replication
chemical_list: D019380:Anti-HIV Agents; D004279:DNA, Viral; D007166:Immunosuppressive Agents; D012367:RNA, Viral; D016572:Cyclosporine